Jump to navigation Jump to search
Stiripentol Wiki Str.png
Clinical data
Routes of
ATC code
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass234.30 g·mol−1

WikiDoc Resources for Stiripentol


Most recent articles on Stiripentol

Most cited articles on Stiripentol

Review articles on Stiripentol

Articles on Stiripentol in N Eng J Med, Lancet, BMJ


Powerpoint slides on Stiripentol

Images of Stiripentol

Photos of Stiripentol

Podcasts & MP3s on Stiripentol

Videos on Stiripentol

Evidence Based Medicine

Cochrane Collaboration on Stiripentol

Bandolier on Stiripentol

TRIP on Stiripentol

Clinical Trials

Ongoing Trials on Stiripentol at Clinical

Trial results on Stiripentol

Clinical Trials on Stiripentol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Stiripentol

NICE Guidance on Stiripentol


FDA on Stiripentol

CDC on Stiripentol


Books on Stiripentol


Stiripentol in the news

Be alerted to news on Stiripentol

News trends on Stiripentol


Blogs on Stiripentol


Definitions of Stiripentol

Patient Resources / Community

Patient resources on Stiripentol

Discussion groups on Stiripentol

Patient Handouts on Stiripentol

Directions to Hospitals Treating Stiripentol

Risk calculators and risk factors for Stiripentol

Healthcare Provider Resources

Symptoms of Stiripentol

Causes & Risk Factors for Stiripentol

Diagnostic studies for Stiripentol

Treatment of Stiripentol

Continuing Medical Education (CME)

CME Programs on Stiripentol


Stiripentol en Espanol

Stiripentol en Francais


Stiripentol in the Marketplace

Patents on Stiripentol

Experimental / Informatics

List of terms related to Stiripentol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Stiripentol (marketed as Diacomit by Laboratoires BIOCODEX) is an anticonvulsant drug used in the treatment of epilepsy. It is unrelated to other anticonvulsants and belongs to the group of aromatic allylic alcohols.

Mechanism of action

As with most anticonvulsants, the precise mechanism is unknown. It has been shown to have anticonvulsant effects on its own. It can prevent the reuptake of GABA and inhibit its metabolism.

It also improves the effectiveness of many other anticonvulsants, possibly due to it inhibiting certain enzymes. This slows the drug's metabolism, increasing blood plasma levels.

Approval history


  • December 2001 - Treatment of severe myoclonic epilepsy in infancy (SMEI). EU orphan designation number EU/3/01/071.

Stiripentol has very limited availability.

Indications and usage

It is indicated as an adjunctive therapy with sodium valproate and clobazam for treating severe myoclonic epilepsy in infancy (SMEI, also know as Dravet's syndrome). Children with SMEI develop often intractable seizures during their first year of life and mental retardation follows. Small-scale trials have show remarkably high response rates, with a significant minority of those treated becoming seizure free.

In addition, it may be used to treat refractory childhood epilepsy in conjunction with carbamazepine. It appears to be less effective in adolescents and adults.


Stiripentol is available as a gelatine capsule (250mg, 500mg) and as a sachet of powder to make a drinkable suspension (250mg, 500mg).

Initial dose is 50 mg/kg per day. This may be increased up to 100 mg/kg per day, with a maximum of 4g. The dose to be divided into two or three with meals. The does of other anticonvulsants may have to be reduced (possibly up to 50%).

Side effects

Side effects are largely due to the increase in plasma concentrations of other anticonvulsants and can be reduced by lowering the does of those drugs. Nausea and vomiting are particularly noted when used in combination with sodium valproate.

Drug interactions

Stiripentol inhibits several cytochrome P450 isoenzymes and so interacts with many anticonvulsants and other medicines. This is both a strength and weakness. It appears to increase the potency of phenobarbital, primidone, phenytoin, carbamazepine, clobazam and diazepam. For example, blood levels of carbamazepine can be maintained whist reducing the dose by 50%.


Tran A, Vauzelle-Kervroedan F, Rey E, Pous G, d'Athis P, Chiron C, Dulac O, Renard F, Olive G. (1996)
[Abstract]. European Journal Clinical Pharmacology. 1996;50(6):497–500.
Perez J, Chiron C, Musial C, Rey E, Blehaut H, d'Athis P, Vincent J, Dulac O. (1999)
[Abstract]. Epilepsia. 1999 Nov;40(11):1618–26.
C. Chiron, M. Marchand, A. Tran, E. Rey, P. d'Athis, J. Vincent, O. Dulac, G. Pons. (2000)
[Abstract]. The Lancet 2000 Nov 11, Volume 356, Issue 9242, Pages 1638–1642
Thanh TN, Chiron C, Dellatolas G, Rey E, Pons G, Vincent J, Dulac O. (2002)
[Abstract]. Arch Pediatr. 2002 Nov;9(11):1120–7.
Chiron C. (2005)
[Abstract]. Expert Opinion on Investigational Drugs July 2005, Vol. 14, No. 7, Pages 905–911]
Trojnar MK, Wojtal K, Trojnar MP, Czuczwar SJ. (2005)
[Full Text]. Pharmacological Reports, 2005, 57, 154-160

External links